

### The anti-inflammatory effect of sulforaphane in the brain

Scarlett Gillespie<sup>1</sup>, Paul Evans<sup>2</sup>, Felicity Gavins<sup>1</sup>. <sup>1</sup>Imperial College, Wolfson Neuroscience Laboratories, London, W12 0NN, United Kingdom, <sup>2</sup>Imperial College, NHLI, London, W12 0NN, United Kingdom.

**Introduction:** Brain inflammation is involved in several neurological pathologies, such as stroke, multiple sclerosis and Alzheimer's disease<sup>1</sup>, which continue to have unmet clinical needs. Consequently, research for efficacious anti-inflammatory agents is ongoing. Sulforaphane (SFN), an isothiocyanate derived from cruciferous vegetables, has been widely studied in the field of oncology where its beneficial effects have been numerous<sup>2</sup>. More recently, SFN's protective effects following damage to the brain have indicated similar protective effects<sup>3, 4</sup>. The effect of SFN on leukocyte-endothelial interactions has yet to be visualised.

**Aim:** To investigate the ability of sulforaphane (i.p, 5mgkg<sup>-1</sup>) to protect the cerebral microvasculature against experimental endotoxaemia.

**Methods and Results:** Intra vital microscopy was used to visualise the cerebral microvasculature. C57Bl6 mice were anaesthetised with Ketamine (150mgkg<sup>-1</sup>)/Xylazine(7.5mgkg<sup>-1</sup>), cannulated via the jugular vein and injected with Rhodamine 6G, a fluorescent dye taken up by leukocytes. Preliminary data indicated neither sham surgery nor systemic saline increased leukocyte-endothelial interactions, whereas; LPS (i.p, 4mgkg<sup>-1</sup>) caused a significant increase in leukocyte-endothelial measured as indicated by increased cell flux (1.4±0.7 cells/min in sham/1.05±0.3 cells/min in saline treated vs. 6.8±1.7 cells/min in LPS treated mice), decreased rolling velocity (431.7±242.6 µm/sec in sham/ 286.1±112.9 µm/sec in saline treated vs. 22.8±2.2 µm/sec in LPS treated mice) and increased numbers of adherent cells (0.1±0.1cells/min/100µm in sham/ 0.7±0.5 in saline treated vs. 5.2±0.8cells/min/100µm in LPS treated mice). No significant leukocyte-endothelial interaction was observed in arterioles in any mice.

Following this model establishment the effect of systemic prophylactic SFN (4mg/kg) was investigated. SFN significantly reduced cell flux, (6.8 cells/min in LPS treated mice vs. 1.1±0.4 cells/min in SFN/LPS treated mice), increased rolling velocity (22.8 µm/sec in LPS treated mice vs. 79.7±22.6 µm/sec in SFN/LPS treated mice) and decreased cell adhesion (5.2 cells/min/100µm in LPS treated mice vs. 1.7±0.6 cells/min/100µm in SFN/LPS treated mice) in pial venules when compared to mice treated with LPS alone; and significantly reduced cell adhesion (1.7 cells/min/100µm in SFN/LPS treated mice vs. 4.2±0.8 cells/min/100µm in corn oil/LPS treated mice) in SFN/LPS treated mice treated compared with corn oil (SFN vehicle)/LPS treated mice. Statistical analysis was performed using ANOVA and Bonferroni post-hoc test. *P*<0.05. n= 4 sham surgery mice; n=6 mice in all other groups.

**Conclusion:** These results indicate that systemic LPS infection induces an inflammatory response within the brain. Furthermore, prophylactic systemic administration of SFN reduces leukocyte-endothelial interactions within the cerebral microvasculature. These novel results suggest SFN as a possible therapeutic strategy in the resolution of inflammation.

1. Lucas SM, Rothwell N, Gibson R (2006). The role of inflammation in CNS injury and disease *Brit J Pharmacol* 147, S232–S240
2. Clarke JD, Dashwood RH, Ho E (2008) Multi-targeted prevention of cancer by sulforaphane *Cancer Lett.* **269**(2):291-304.
3. Zhao J, Kobori N, Aronowski J, Dash PK (2006) Sulforaphane reduces infarct volume following focal cerebral ischemia in rodents. *Neurosci Lett.* **393**(2-3):108-12.
4. Zhao J, Moore AN, Redell JB, Dash PK (2007) Enhancing expression of Nrf2-driven genes protects the blood brain barrier after brain injury. *J Neurosci.* **19**;27(38):10240-8.